Article Text

Download PDFPDF
EP487 Panoramic view of endometrioid endometrial cancer in turkey: a retrospective, multicenter study of turkish society of gynecologic oncology (TRSGO-END002)
  1. E Çelik1,
  2. V Gülseren2,
  3. B Özge Kayan3,
  4. M Öz4,
  5. E Kocaman5,
  6. S Akgöl6,
  7. S Alemdoroğlu7,
  8. S Topuz1,
  9. K Güngördük2,
  10. F Demirkiran3,
  11. MM Meydanli4,
  12. Ö Akbayir6,
  13. H Çelik7 and
  14. A Ayhan5
  1. 1Gynecologic Oncology, Istanbul University, Istanbul Faculty of Medicine, Istanbul
  2. 2Gynecologic Oncology, Tepecik Education and Research Hospital, İzmir
  3. 3Gynecologic Oncology, İstanbul University Cerrahpaşa, Istanbul
  4. 4Gynecologic Oncology, Zekai Tahir Burak Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Anakara
  5. 5Gynecologic Oncology, Baskent University Faculty of Medicine, Ankara
  6. 6Gynecologic Oncology, Kanuni Sultan Suleyman Teaching and Research Hospital, University of Health Sciences, Faculty of Medicine, Istanbul
  7. 7Obstetrics and Gynecology, Başkent University Adana Teaching and Research Center, Adana, Turkey


Introduction/Background The purpose of this study was to investigate prognostic factors associated with overall survival (OS) in endometrioid endometrial cancer (EC).

Methodology A multicenter, retrospective department database review was performed to identify patients with endometrioid EC at seven high-volume gynecologic oncology centers in Turkey. A total of 4993 women who had undergone primary surgery between 1999 and 2018 were included. Women were staged according to the 2009 FIGO staging system. Kaplan-Meier method was used to generate survival data. Factors predictive of outcome were analyzed using Cox proportional hazards models.

Results Three thousand two hundred and nineteen women (64.5%) were classified as stage IA, 1034 (20.7%) as IB, 286 (5.7%) as II, 72 (1.4%) as IIIA, 15 (0.3%) as IIIB, 173 (3.55) as IIIC1, 128 (2.6%) as IIIC2, and 66 (1.3%) as stage IV. The median age at surgery was 58 years (range, 21–94 years), and the median duration of follow-up was 47 months (range, 3–227 months). For the entire cohort, the 5-year disease-free survival was 75.1% whereas the 5-year OS was 82.2%. Age ≥60 years (Hazard ratio [HR]: 1.21, 95% confidence interval [CI]:1.06–1.40; p=0.005), myometrial invasion (MMI) ≥1/2 (HR: 1.19, 95% CI:1.02–1.41; p=0.02), lymphovascular space invasion (LVSI) (HR: 1.29, 95% CI:1.05–1.58; p=0.01), and baseline serum CA 125 ≥35 U/ml (HR: 1.29, 95% CI:1.08-1.55; p=0.005) were identified as independent prognostic factors for decreased OS.

Conclusion Age ≥60 years, MMI ≥1/2, LVSI, and baseline serum CA 125≥35 U/ml seem to be independent prognostic factors for decreased OS in Turkish endometrioid EC population.

Disclosure Nothing to disclose.

Abstract EP487 Table 1

Clinicopathological characteristics of 4993 endometrioid endometrial cancer patients undergoing surgery

Abstract EP487 Table 2

Univariate and multivariate analyses of 4993 women with endometrioid endometrial cancer undergoing surgery with regard to disease-free survival

Abstract EP487 Table 3

Univariate and multivariate analyses of 4993 women with endometrioid endometrial cancer undergoing surgery with regard to overall survival

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.